The promise and reality of cancer gene therapy

American Journal of Human Genetics

Volumn 61, Issue 4, 1997, Pages 785-789

  Hall, Simon J ^a   Chen, Shu Hsia ^a   Woo, Savio L C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CONTROL; CANCER INHIBITION; CELL CONTACT; CELL KILLING; DNA REPAIR; GENE MUTATION; GENE THERAPY; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0030804591     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/514898     Document Type: Article

References (58)

1. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL (1995) Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 92: 8522-8526
2. Barba D, Hardin J, Sadelin M, Gage FH (1994) Development of antitumor immunity following thymidine kinase-based killing of experimental brain tumors. Proc Natl Acad Sci USA 91:4348-4352
3. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Mg L, et al (1996) An adenovirus mutant that replicates selectively in p53 deficient human tumor cells. Science 274: 373-376
4. Bookstein R, Demers W, Gregory R, Maneval D, Park J, Wills K (1996) p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol 23:66-67
5. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL (1996) Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 7:1995-2002
6. Brand K, Arnold W, Bartels T, Lieber A, Kay MA, Strauss M, Dorken B (1997) Liver-associated toxicity of the HSV-tk/ GCV approach and adenoviral vectors. Cancer Gene Ther 4:9-16
7. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann J-L, Klatzmann D (1993) Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 90:7024-7028
8. Caruso M, Pham-Nguyen K, Kwong Y-L, Xu B, Kosai K-I, Finegold M, Woo SLC, et al (1996) Adenovirus-mediated interleukin-12 gene therapy for metastatic colon cancer. Proc Natl Acad Sci USA 93:11302-11306
9. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, et al (1992) Costimulation of antitumor immunity by B7 countereceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102
10. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE (1994a) Tumor immunogenicity determines the effect of B7 co-stimulation on T cell-mediated tumor immunity. J Exp Med 179:523-532
11. Chen S-H, Chen XHL, Wang Y, Kosai KI, Finegold MJ, Rich SS, Woo SLC (1995) Combination gene therapy for liver metastases of colon carcinoma in vivo. Proc Natl Acad Sci USA 92:2577-2581
12. Chen S-H, Kosai KI, Xu B, Pham-Nguyen K, Contant C, Finegold MJ, Woo SLC (1996) Combination suicide and cytokine gene therapy for hepatic métastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 56:3758-3762
13. Chen S-H, Shine HD, Goodman JC, Grossman RG, Woo SLC (1994b) Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 91:3054-3057
14. Chong H, Hutchinson G, Hart IR, Vile RG (1996) Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum Gene Ther 7:1771-1779
15. Consalvo M, Mullen CA, Modesti A, Musiano P, Allione A, Cavallo F, Giovarelli M, et al (1995) 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves efficient memory. J Immunol 154:5302-5312
16. Cordier L, Duffour MT, Sabourin JC, Lee MG, Cabannes J, Ragot T, Perricaudet M, et al (1995) Complete recovery of mice from a pre-established tumor by direct intra-tumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther 2:16-21
17. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Sciene 256:1550-1552
18. Dameron K, Vopert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblast by p53 regulation of thrombospondin 1. Science 265:1582-1584
19. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, et al (1993) vaccination with irradiated tumor cells engineered to secrete murine ganuulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
20. Elshami AA, Kucharczuk JC, Zhang HB, Smythe WR, Hwang HC, Litzky LA, Kaiser LR, et al (1996a) Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 7:141-148
21. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, Amin KM et al (1996b) Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 3:85-92
22. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, et al (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403
23. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA (1994) Therapeutic effect of a retroviral wildtype p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86:1458-1462
24. +-mediated rejection of established tumors. Hum Gene Ther 8:477-488
25. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990a) Retroviral vector-mediated g-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820-7825
26. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990b) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224
27. Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ (1995) Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14:275-285
28. Hamel W, Magnelli L, Chiarugi VP, Israel MA (1996) Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 56:2697-2702
29. Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442-1455
30. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3:639-645
31. Hendrzak JA, Brunda MJ (1995) Interleukin-12: biologic activity, therapeutic utility, and role in disease. Lab Invest 72: 619-637
32. Huber BE, Austin EA, Good SS, Knick VC, Tobbels S, Richards CA (1993) In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 53:4619-4626
33. Kanai F, Lan K-H, Shiratori Y, Tanaka T, Ohashi M, Okudaira T, Yoshida Y, et al (1997) In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 57:461-465
34. Khil MS, Kim JH, Mullen CA, Lim SH, Freytag SO (1996) Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res 2:53-57
35. Kim JH, Kim SH, Kolozsvary A, Brown SL, Lim OB, Freytag SO (1995) Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 33:861-868
36. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ (1995) Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 6:395-405
37. Linsley PS, Ledbetter JA (1993) The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11: 199-212
38. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, et al (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810
39. Mesnil M, Piccoli C, Tirabi G, Willecke K, Yamasaki H (1996) Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 93:1831-1835
40. Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer controll strategy. Cancer Res 46:5276-5281
41. Mullen CA, Coale MM, Lowe R, Blaese RM (1994) Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 54:1503-1506
42. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA (1996) Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 112:1372-1377
43. Ohwada A, Hirschowitz EA, Crystal RG (1996) Regional delivery of an adenovirus containing the escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum Gene Ther 7:1567-1576
44. Porgador A, Banneji R, Waanabe Y, feldman M, Gilboa E, Eisenbach L (1993a) Antimetastatic vaccination of tumor-bearing mice with two types of IFN-g gene-inserted tumor cells. J Immunol 150:1458-1470
45. Porgador A, Gansbacher B, Bannerji R, Tezhoval E, Gilboa E, Feldman M, Eisenbach L (1993b) Anti-metastatic vaccination of tumor bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer 53:471-477
46. Qian C, Idoate M, Bilbao R, Sangro B, Bruna O, Vazquez J, Prieto J (1997) Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum Gene Ther 8:349-358
47. Richards CA, Austin EA, Huber BE (1995) Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor specific gene therapy. Hum Gene Ther 6:881-893
48. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, et al (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985-991
49. Salvadori S, Gansbacher B, Wernick I, Tirelli S, Zier K (1995) B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum Gene Ther 6:1299-1306
50. Tong X-W, Block A, Chen S-H, Contant CF, Agoulnik I, Blankenberg K, Kaufman RH, et al (1996) In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transducrion and ganciclovir administration. Gynecol Oncol 61:175-179
51. + T cells by B-7 transfected melanoma cells. Science 259:368-370
52. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE (1995) Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-flurocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma line. Cancer Res 55:4808-4812
53. Vieweg J, Rosenthal FM, Bannerji R, Heston WDW, Fair WR, Gansbacher B, Gilboa E (1994) Immunotherapy of prostate cancer in the dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54:1760-1765
54. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-tk gene involves an immune component. Cancer Res 54:6226-6234
55. Wu T-C, Huang AYC, Jaffee EM, Levitsky HI, Pardoll DM (1995) A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 182:1415-1421
56. Xu M, Kumar D, Srinivas S, Detolla LJ, Yu SF, Stass SA, Mixson AJ (1997) Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther 8:177-185
57. Yamamoto S, Suzuki S, Hoshino A, Akimoto M, Shimada T (1997) Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cells induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther 4:91-96
58. Yee D, McGuire SE, Brunner N, Kozelsky TW, Allred DC, Chen S-H, Woo SLC (1996) Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther 7:1251-1257